Skip to main content
Equibles
LMAT logo

LMAT · Lemaitre Vascular Inc · Documents

Track LMAT — free

Use LMAT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LMAT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$78.29 +0.64 (+0.82%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.79B
Shares
22.88M
Volume · Nov 13 200.09K Avg daily vol (3M) 288.13K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $249.6M up 13.5% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $67.97M up 11.3% 10-Q filed Nov 5, 2026 Latest results Q3 sales rose 11%; dividend set at $0.25/share 8-K filed Nov 4, 2026 Earnings call Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month sales rise 11%, gross margin expands to 72.2%

For the nine months ended September 30, 2026, LeMaitre reported net sales of $204.9 million, up 11% from $185.1 million, while gross profit rose 12% to $147.9 million and gross margin increased to 72.2% from 71.5%.

Revenue $67.97M ▲ 11.3% Net income $15.02M ▼ 13.5% Diluted EPS $0.65 ▼ 13.3%
Read from the MD&A section
3 source passages
Net sales increased by $19.8 million, or 11%, to $204.9 million for the nine months ended September 30, 2026, compared to $185.1 million for the nine months ended September 30, 2025. Gross profit increased $15.5 million, or 12%, to $147.9 million for the nine months ended September 30, 2026, as compared to $132.3 million for the nine months ended September 30, 2025, and gross margin increased by 70 basis points to 72.2% in the period, as compared to 71.5% for the nine months ended September 30, 2025. acquiring complementary devices and transitioning distributor sales to LeMaitre; Open the document at this passage
Nov 4
Earnings call
Q3 organic revenue growth reached 12%

LeMate reported Q3 2026 organic revenue growth of 12%, with 71.7% gross margin and 26% operating margin; it reiterated 11 percent full-year organic revenue growth guidance after acquiring vascular assets for $19.2 million.

5 source passages
LeMate's Q3 organic revenue growth of 12% consisted of 7% price and 5% units. In Q3, 2026, gross margin was 71.7%. Q3 2026 operating income was $17.7 million, resulting in a 26% operating margin. For 2026, we have reiterated our 11 percent organic revenue growth guidance for the year. We acquired a portfolio of vascular assets from B. Braun in October for total consideration of $19.2 million. Open the document at this passage
Nov 4
Current report 8-K
Q3 sales rose 11%; dividend set at $0.25/share

LeMaitre Vascular reported Q3 2026 sales of $68.0mm, up 11% (12% organic), and EPS of $0.65. The board approved a $0.25/share dividend payable December 3, 2026.

Financial results
4 source passages
LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Sales $68.0mm, +11% (+12% organic) vs. Q3 2025 EPS $0.65 (-14%, +5% vs. adjusted) On October 27, 2026, the Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026. Open the document at this passage
Oct 15
Current report 8-K Events of Oct 9
Director or officer change, or executive pay

LeMaitre Vascular, Inc. announced that David B. Roberts intends to retire as President and employee effective December 31, 2026, while continuing to serve on its Board of Directors.

Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $70.38M ▲ 9.6% Net income $17.05M ▲ 23.7% Diluted EPS $0.74 ▲ 23.3%
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $66.55M ▲ 11.2% Net income $15.68M ▲ 42.4% Diluted EPS $0.68 ▲ 41.7%
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $249.6M ▲ 13.5% Net income $57.73M ▲ 31.1% Diluted EPS $2.52 ▲ 30.6%
2025
Nov 7
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $61.05M ▲ 11.4% Net income $17.36M ▲ 55.8% Diluted EPS $0.75 ▲ 53.1%
Aug 6
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $64.23M ▲ 15.0% Net income $13.78M ▲ 16.5% Diluted EPS $0.60 ▲ 15.4%
May 8
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $59.87M ▲ 12.0% Net income $11.01M ▲ 11.4% Diluted EPS $0.48 ▲ 9.1%
Feb 28
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $219.86M ▲ 13.6% Net income $44.04M ▲ 46.3% Diluted EPS $1.93 ▲ 44.0%
2024
Nov 8
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $54.82M ▲ 15.6% Net income $11.14M ▲ 48.5% Diluted EPS $0.49 ▲ 48.5%
Showing 1–50 of 132 documents
Key facts CIK 1158895 CUSIP 525558201 13F (30d) 255 filings 226 filers Visit website Investor relations